Annexon, Inc. (ANNX)
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders.
The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis.
The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy.
In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications.
The company was incorporated in 2011 and is headquartered in Brisbane, California.
|IPO Date||Jul 24, 2020|
|CEO||Douglas Love Esq., J.D.|
1400 Sierra Point Parkway, Bldg C, Suite 200
Brisbane, California 94005
|Fiscal Year||January - December|
|Douglas Love J.D., Esq.||Chief Executive Officer, President and Director|
|Dr. Larry C. Mattheakis Ph.D.||Executive Vice President and Chief Scientific Officer|
|Dr. Ted Yednock Ph.D.||Executive Vice President, Chief Innovation Officer and Chairman of the Scientific Advisory Board|
|Dr. Arnon Rosenthal Ph.D.||Founder|
|Jennifer Lew||Executive Vice President and Chief Financial Officer|
|Miriam Mason||Senior Vice President of Corporate Communications|
|Michael Overdorf M.B.A.||Executive Vice President and Chief Business Officer|
|Henk-Andre Kroon M.D.||Senior Vice President of Translational Medicine|
|Mirella Villa Del Toro||Secretary|
Latest SEC Filings
|May 25, 2023||8-K||Current Report|
|May 8, 2023||8-K||Current Report|
|May 8, 2023||10-Q||Quarterly Report|
|Apr 25, 2023||ARS||Filing|
|Apr 25, 2023||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Apr 25, 2023||DEF 14A||Other definitive proxy statements|
|Mar 13, 2023||8-K||Current Report|
|Mar 6, 2023||S-8||Securities to be offered to employees in employee benefit plans|
|Mar 6, 2023||8-K||Current Report|
|Mar 6, 2023||10-K||Annual Report|